- Austria and Denmark to work with Israel on future Covid jabs
- Germany and France under pressure to shift Oxford vaccine
- Weekend lockdown in Paris would be ‘inhumane’, says mayor
- Brazil variant evaded up to 61% of immunity in previous Covid cases
- See all our coronavirus coverage
Slovakia imposed an overnight curfew from Wednesday, with a government decree banning residents from leaving home between 8pm and 5am.
During the day, Slovaks are being asked to stay at homes other than for a few exempted reasons, including medical visits, work and outdoor exercise or walking pets, AFP reports.
The high rate “is due to many factors, Slovakia has made several mistakes,” Doctors’ Trade Union Association chairman Peter Visolajsky told the agency.
“The lockdown was introduced too late and it is not sufficiently monitored. Also, this mortality rate is caused by the overall bad condition of Slovak healthcare,” Visolajsky said.
One dose of either Pfizer-BioNTech’s or AstraZeneca’s COVID-19 vaccine helps to prevent disease severe enough to require hospitalisation of people in their 80s with other illnesses, interim data from a UK study shows.
Reuters reported the findings, which found that one dose of the Pfizer-BioNTech shot was 71.4% effective from 14 days at preventing symptomatic illness severe enough to result in hospitalisation among patients with a median age of 87 years.
For the AstraZeneca vaccine, the results showed it was 80.4% effective by the same measures among patients with an average age of 88.
“These early results show the UK COVID-19 vaccine programme is working better than we could have hoped,” said Adam Finn, a professor of paediatrics and chief investigator of the AvonCAP study at Britain’s University of Bristol.